Royal Bank of Canada Buys 470,882 Shares of Sanofi $SNY

Posted by Brian Himes on Jul 31st, 2026

Royal Bank of Canada lifted its position in Sanofi (NASDAQ:SNY – Free Report) by 17.5% during the first quarter, HoldingsChannel.com reports. The fund owned 3,155,080 shares of the company’s stock after purchasing an additional 470,882 shares during the period. Royal Bank of Canada’s holdings in Sanofi were worth $152,011,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC grew its holdings in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after purchasing an additional 1,869 shares during the period. AQR Capital Management LLC raised its holdings in Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after purchasing an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Sanofi by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after purchasing an additional 752 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in shares of Sanofi by 5.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after buying an additional 347 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Sanofi by 36.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $159,000 after buying an additional 875 shares during the period. Institutional investors own 14.03% of the company’s stock.

Analysts Set New Price Targets

SNY has been the topic of several research analyst reports. Argus raised Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Morgan Stanley set a $49.00 price target on Sanofi in a report on Wednesday, July 8th. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Finally, BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $49.50.

View Our Latest Research Report on SNY

Key Stories Impacting Sanofi

Here are the key news stories impacting Sanofi this week:

Positive Sentiment: Sanofi reported second-quarter adjusted earnings of $1.19 per share, ahead of the $1.10 analyst consensus, while revenue rose 16% year over year to $14.04 billion, exceeding expectations. Sanofi quarterly earnings report
Positive Sentiment: Sales of Dupixent, Sanofi’s key asthma and immunology drug, continued to drive growth and reportedly surpassed €5 billion for the quarter for the first time. The strength prompted Sanofi to raise its 2026 outlook, calling for approximately 10% sales growth excluding currency effects, with business earnings per share expected to grow slightly faster. Reuters Sanofi sales outlook article
Neutral Sentiment: Unusual options activity saw traders purchase about 4,046 call options, roughly 74% above typical daily call volume. This indicates increased speculative interest but does not establish a clear direction for the stock.
Negative Sentiment: Despite the earnings beat, investors focused on setbacks in Sanofi’s pipeline and concerns about weak decision-making in research and development. New CEO Belen Garijo said the company would pursue a more disciplined R&D strategy and work to rebuild its drug-development engine, highlighting execution risks and the need for future pipeline successes. Sanofi R&D strategy article

Sanofi Trading Down 4.4%

Shares of NASDAQ:SNY opened at $42.89 on Friday. Sanofi has a 12 month low of $40.89 and a 12 month high of $52.68. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The company’s fifty day simple moving average is $43.46 and its 200 day simple moving average is $45.22. The firm has a market cap of $103.98 billion, a price-to-earnings ratio of 11.98, a PEG ratio of 1.13 and a beta of 0.34.

Sanofi Company Profile

(Free Report)

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.